Biotech · Private company
RayzeBio, Inc.
Track this companyFree. Adds RayzeBio, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials77 recruiting or active
Pipeline programs16From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline16
- EverolimusPhase 3 · GEP-NETClinicalTrials.gov · fetched Nov 12, 2026
- LanreotidePhase 3 · GEP-NETClinicalTrials.gov · fetched Nov 12, 2026
- OctreotidePhase 3 · GEP-NETClinicalTrials.gov · fetched Nov 12, 2026
- RYZ101Phase 3 · GEP-NETClinicalTrials.gov · fetched Nov 12, 2026
- SunitinibPhase 3 · GEP-NETClinicalTrials.gov · fetched Nov 12, 2026
- PSMA PET/CTPhase 2 · Prostate Cancer (Adenocarcinoma)ClinicalTrials.gov · fetched Nov 12, 2026
- RYZ101Phase 2 · Metastatic Breast CancerClinicalTrials.gov · fetched Nov 12, 2026
- RYZ711Phase 2 · Prostate Cancer (Adenocarcinoma)ClinicalTrials.gov · fetched Nov 12, 2026
- RYZ801Phase 2 · Hepatocellular Carcinoma (HCC)ClinicalTrials.gov · fetched Nov 12, 2026
- RYZ811Phase 2 · Hepatocellular Carcinoma (HCC)ClinicalTrials.gov · fetched Nov 12, 2026
- AtezolizumabPhase 1 · SCLC,Extensive StageClinicalTrials.gov · fetched Nov 12, 2026
- CarboplatinPhase 1 · SCLC,Extensive StageClinicalTrials.gov · fetched Nov 12, 2026
- RYZ101 Dose Level 1Phase 1 · SCLC,Extensive StageClinicalTrials.gov · fetched Nov 12, 2026
- RYZ101 Dose Level 2Phase 1 · SCLC,Extensive StageClinicalTrials.gov · fetched Nov 12, 2026
- RYZ101 Dose Level 3Phase 1 · SCLC,Extensive StageClinicalTrials.gov · fetched Nov 12, 2026
- RYZ401Phase 1 · GEP-NETClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- RYZ711 Diagnostic Platform StudyPHASE1_PHASE2 · NOT_YET_RECRUITING · started Oct 1, 2026ClinicalTrials.gov NCT07862582 · fetched Nov 12, 2026
- Study of RYZ401 in Subjects With Solid Tumors Expressing SSTRs.PHASE1 · RECRUITING · started Dec 3, 2025ClinicalTrials.gov NCT07165132 · fetched Nov 12, 2026
- RYZ101 for the Treatment of Progressive or Recurrent Intracranial MeningiomaPHASE1_PHASE2 · RECRUITING · started Nov 12, 2025ClinicalTrials.gov NCT07150806 · fetched Nov 12, 2026
- Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCCPHASE1_PHASE2 · RECRUITING · started Sep 5, 2025ClinicalTrials.gov NCT06726161 · fetched Nov 12, 2026
- Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.PHASE1_PHASE2 · RECRUITING · started Jul 19, 2024ClinicalTrials.gov NCT06590857 · fetched Nov 12, 2026
- Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLCPHASE1 · ACTIVE_NOT_RECRUITING · started Oct 10, 2022ClinicalTrials.gov NCT05595460 · fetched Nov 12, 2026
- Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA TherapyPHASE3 · ACTIVE_NOT_RECRUITING · started Mar 24, 2022ClinicalTrials.gov NCT05477576 · fetched Nov 12, 2026